Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsNZSE:AFT -0.63%93 EV-to-EBITDA is 19.57 as of Aug. 06, 2026, which is 8% above its 10-year median of 18.09. GuruFocus rates NZSE:AFT with a GF Score™ of 93/100 and a GF Value™ of NZ$4.24 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 743 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 66.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AFT Pharmaceuticals's enterprise value is NZ$543.9 Mil.
AFT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$27.8 Mil. Therefore, AFT Pharmaceuticals's EV-to-EBITDA for today is 19.57.
The historical rank and industry rank for AFT Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NZSE:AFT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.74 Med: 18.09 Max: 63.97
Current: 19.56
During the past 11 years, the highest EV-to-EBITDA of AFT Pharmaceuticals was 63.97. The lowest was -28.74. And the median was 18.09.
NZSE:AFT's EV-to-EBITDA is ranked worse than 66.08% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs NZSE:AFT: 19.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AFT Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
AFT Pharmaceuticals's share price for today is NZ$4.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AFT Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EV-to-EBITDA falls into.
AFT Pharmaceuticals's current Enterprise Value is NZ$543.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$27.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (NZSE:AFT) has a EV-to-EBITDA of 19.57 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AFT Pharmaceuticals. This is near median its historical median of 18.09. According to the industry distribution chart, AFT Pharmaceuticals ranks #491 out of 743 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is AFT Pharmaceuticals' EV-to-EBITDA too high?
AFT Pharmaceuticals' current EV-to-EBITDA of 19.57 is near median its 10-year median of 18.09. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. AFT Pharmaceuticals' value of 19.57 is 49.8% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #491 out of 743 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #491 out of 743 companies for EV-to-EBITDA. This places AFT Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. AFT Pharmaceuticals' value of 19.57 is 49.8% above this benchmark. While the company's 10-year median is 18.09 vs. the industry median of 13.06, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current EV-to-EBITDA of 19.57 is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AFT Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current EV-to-EBITDA is 19.57, which is near median its own 10-year median of 18.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Overvalued. The stock's GF Value™ is NZ$4.24, compared to a current price of NZ$4.75 — trading 12% above its estimated fair value. The current EV-to-EBITDA is 19.57, which is near median its 10-year median of 18.09 and 49.8% above the Drug Manufacturers industry median of 13.06. AFT Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current EV-to-EBITDA is 19.57 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of NZ$4.75 is trading 12% above its estimated GF Value™ of NZ$4.24.
GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for NZSE:AFT:
EV-to-EBITDA: 19.57 (near median its 10-year median of 18.09)
GF Value™: NZ$4.24 vs. price of NZ$4.75 (12% above fair value)
Industry Position: 49.8% above the Drug Manufacturers median (#491 of 743)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
93GF Score
Get the complete analysis for NZSE:AFT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
